Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT) | Zendy

Aaltje Y Adema | Zendy; Maarten A. de Jong | Zendy; Martin H. de Borst | Zendy; Pieter M. ter Wee | Zendy; Marc G. Vervloet | Zendy

Open Access

Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

Author(s) -

Aaltje Y Adema,

Maarten A. de Jong,

Martin H. de Borst,

Pieter M. ter Wee,

Marc G. Vervloet

Publication year - 2016

Publication title -

the nephron journals/nephron journals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.951

H-Index - 72

eISSN - 2235-3186

pISSN - 1660-8151

DOI - 10.1159/000448184

Subject(s) - sevelamer , medicine , fibroblast growth factor 23 , phosphate binder , kidney disease , hypophosphatemia , phosphate , renal function , endocrinology , urology , proteinuria , regimen , gastroenterology , kidney , hyperphosphatemia , parathyroid hormone , biochemistry , calcium , chemistry

Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). Preliminary data suggest that interventions lowering gastro-intestinal phosphate uptake lowers serum FGF23 concentrations and improves cardiovascular risk and subsequently survival. However, data are lacking about the magnitude of effects, the effect in different stages of CKD and whether there is a dose-effect relationship.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research